Related Experiment Video
Updated: Jan 19, 2026

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
Published on: June 23, 2023
Orthostatic hypotension in Parkinson disease: A 7-year prospective population-based study
Ylva Hivand Hiorth1, Kenn Freddy Pedersen2, Ingvild Dalen2
1From the Department of Physical Medicine and Rehabilitation (Y.H.H.), The Norwegian Centre for Movement Disorders (Y.H.H., K.F.P., G.A.), Department of Neurology (K.F.P., G.A.), and Department of Research, Section of Biostatistics (I.D.), Stavanger University Hospital; Department of Clinical Medicine (O.-B.T.), University of Bergen; Department of Neurology (O.-B.T.), Haukeland University Hospital, Bergen; and Department of Chemistry, Bioscience and Environmental Engineering (G.A.), University of Stavanger, Norway. ylva.hivand.hiorth@sus.no.
Objective:
To determine the frequency, evolution, and associated features of orthostatic hypotension (OH) over 7 years of prospective follow-up in a population-based, initially drug-naive Parkinson disease (PD) cohort.
Methods:
We performed repeated lying and standing blood pressure measurements in 185 patients with newly diagnosed PD and 172 matched normal controls to determine the occurrence of (1) OH using consensus-based criteria and (2) clinically significant OH (mean arterial pressure in standing position ≤75 mm Hg). We applied generalized estimating equations models for correlated data to investigate associated features of these 2 outcomes in patients with PD.
Results:
OH was more common in patients with PD than controls at all visits, with the relative risk increasing from 3.0 (95% confidence interval [CI] 1.6-5.8; p < 0.001) at baseline to 4.9 (95% CI 2.4-10.1; p < 0.001) after 7 years. Despite a high cumulative prevalence of OH (65.4%) and clinically significant OH (29.2%), use of antihypotensive drugs was very rare (0.5%). OH was independently associated with older age (odds ratio [OR] 1.06 per year; 95% CI 1.03-1.10), lower Mini-Mental State Examination score (OR 0.91 [0.85-0.97] per unit), and longer follow-up time (OR 1.12 [1.03-1.23] per year). Clinically significant OH was associated with the same characteristics, in addition to higher levodopa equivalent dosage (OR 1.16 [1.07-1.25] per 100 mg).
Conclusions:
In this population-based study, we found OH to be a very frequent but undertreated complication in early PD, with associations to both disease-specific symptoms and drug treatment. Our findings suggest that clinicians should more actively assess and manage OH abnormalities in PD.
Related Concept Videos
06:07Histological Examination of Mitochondrial Morphology in a Parkinson's Disease Model
03:20Measuring Constipation in a Drosophila Model of Parkinson's Disease
09:19Community-based Adapted Tango Dancing for Individuals with Parkinson's Disease and Older Adults
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
23:53Ole Isacson: Development of New Therapies for Parkinson's Disease
Prospect Theory

